Shots:
- The EMA has accepted the MAA of Linerixibat to treat cholestatic pruritus in pts with primary biliary cholangitis (PBC)
- MAA was supported by the P-III (GLISTEN) study (n=238), which showed that Linerixibat significantly and sustainably improved cholestatic pruritus and itch-related sleep interference, meeting all 1EPs & 2EPs. The safety profile aligned with previous studies. Conducted across 19 countries; presented at the EASL’25
- Linerixibat is an oral IBAT inhibitor that targets cholestatic pruritus in PBC by blocking bile acid reuptake, thereby reducing itch-related mediators in circulation
Ref: GSK | Image: GSK| Press Release
Related News:- GSK Receives the US FDA’s Approval for Benlysta to Treat Active Lupus Nephritis (LN)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
